Author:
Reguart Noemi,Reyes Roxana, ,
Funder
This article is published under the Creative Commons Attribution Non-commercial License.
Publisher
Touch Medical Media, Ltd.
Reference63 articles.
1. Paik PK, Pillai RN, Lathan CS, et al. New treatment options in advanced squamous cell lung cancer.Am Soc Clin Oncol Educ Book. 2019;39:e198–e206.
2. Li T, Kung HJ, Mack PC, Gandara DR. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol. 2013;31:1039–49.
3. Gandara DR, Hammerman PS, Sos ML, et al. Squamous cell lung cancer: from tumor genomics to cancer therapeutics. Clin Cancer Res. 2015;21:2236–43.
4. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22:2184–91.
5. Al-Saleh K, Quinton C, Ellis PM. Role of pemetrexed in advanced non-small-cell lung cancer:meta-analysis of randomized controlled trials, with histology subgroup analysis. Curr Oncol. 2012;19:e9–15.